Advances in chemical biology and chemical genomics and studies of biomolecular interactions and biomolecular structures have resulted in a targeted approach to study diseases. New targets are being identified for various therapeutic areas. The new imperative is to design and synthesize new chemical entities as collections of small molecule screening libraries. These focused skeletally diverse collections of molecules could help understand structure activity relationships (SAR) from small molecule screens.
The ChemDiscovery Platform™ is based on structural analysis of different target families like G-protein coupled receptors, kinases and ion channels and novel potential privileged structures like spirocycles, bicyclic and tricyclic templates containing bridgehead heterocyclic atoms. This analysis then serves to be able to provide a novel collection of compounds, and templates which are drug like and not target dependent. These substructure compounds then serve as a starting point for both early drug discovery (broad based screening) and lead optimization (focused hit to lead screening) research programs.
With the new model for drug discovery, involving the external collaboration for R&D programs in pharmaceutical, agrochemical and biotechnology companies chemists in the outsourced companies normally do the early discovery phase synthesis of screening compounds, with the remaining part of the discovery process being done within the pharmaceutical company using the medicinal and process chemists to do the hit to lead and process development of the hit compound. The ChemDiscovery Platform™ for drug discovery helps translate novel therapeutic strategies into significant advantages over current drug targets by allowing for the seamless integration of the early stage discovery along with the medicinal chemistry and process chemistry. Design of appropriate chemical scaffolds, building blocks and chemical arrays allows for the creation of novel small molecule collections which help modulate all aspects of human biology and undruggable targets.
For more information contact us at info@chemroutes.com